SAN

83.69

-0.14%↓

MRK1

111.4

+0.36%↑

SHL.DE

46.65

+0.26%↑

ARGX

490

-0.71%↓

FRE

41.21

+0.39%↑

SAN

83.69

-0.14%↓

MRK1

111.4

+0.36%↑

SHL.DE

46.65

+0.26%↑

ARGX

490

-0.71%↓

FRE

41.21

+0.39%↑

SAN

83.69

-0.14%↓

MRK1

111.4

+0.36%↑

SHL.DE

46.65

+0.26%↑

ARGX

490

-0.71%↓

FRE

41.21

+0.39%↑

SAN

83.69

-0.14%↓

MRK1

111.4

+0.36%↑

SHL.DE

46.65

+0.26%↑

ARGX

490

-0.71%↓

FRE

41.21

+0.39%↑

SAN

83.69

-0.14%↓

MRK1

111.4

+0.36%↑

SHL.DE

46.65

+0.26%↑

ARGX

490

-0.71%↓

FRE

41.21

+0.39%↑

Search

Laboratorios Farmaceuticos Rovi SA

Chiusa

SettoreSettore sanitario

53.3 -1.66

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

52.75

Massimo

54.2

Metriche Chiave

By Trading Economics

Entrata

-9.3M

23M

Vendite

-280M

155M

P/E

Media del settore

20.183

39.857

EPS

0.354

Rendimento da dividendi

1.71

Margine di Profitto

14.752

Dipendenti

2,197

EBITDA

-107M

31M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+65.75% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.71%

2.42%

Utili prossimi

24 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

20M

2.8B

Apertura precedente

54.96

Chiusura precedente

53.3

Notizie sul Sentiment di mercato

By Acuity

100%

0%

365 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 lug 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 lug 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 lug 2025, 21:04 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 lug 2025, 23:43 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 lug 2025, 22:47 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 lug 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 lug 2025, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lug 2025, 22:30 UTC

Discorsi di Mercato
Utili

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

17 lug 2025, 22:20 UTC

Discorsi di Mercato
Utili

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 lug 2025, 22:04 UTC

Discorsi di Mercato
Utili

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 lug 2025, 22:03 UTC

Acquisizioni, Fusioni, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 lug 2025, 21:58 UTC

Discorsi di Mercato
Utili

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 lug 2025, 21:57 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:47 UTC

Utili

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 lug 2025, 21:45 UTC

Discorsi di Mercato

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 lug 2025, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 lug 2025, 21:22 UTC

Acquisizioni, Fusioni, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 21:05 UTC

Utili

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lug 2025, 21:04 UTC

Acquisizioni, Fusioni, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 lug 2025, 21:02 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lug 2025, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

17 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Laboratorios Farmaceuticos Rovi SA Previsione

Obiettivo di Prezzo

By TipRanks

65.75% in crescita

Previsioni per 12 mesi

Media 90 EUR  65.75%

Alto 90 EUR

Basso 90 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Laboratorios Farmaceuticos Rovi SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

51.1 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

365 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.